A non-selective S1P receptor modulator, called fingolimod, which disrupts lymphocyte trafficking by trapping the CCR7+ T cells in LNs is already used as a therapeutic agent in multiple sclerosis [168,169]. Here, CCR7 is linked to multiple sclerosis.